← All trials
NCT04527211
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 7, 2020
- Primary completion
- Nov 30, 2020
- Completion date
- Dec 16, 2020
- First posted
- Aug 26, 2020
- Last posted
- Aug 26, 2020
- Enrollment
- 550
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pontificia Universidad JaverianaLead sponsor
- Pontificia Universidad JaverianaReponsible party - principal investigator
- Pontificia Universidad JaverianaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.